01:26:50 Europe / Stockholm

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-03-28 Årsstämma 2024
2024-02-15 Bokslutskommuniké 2023
2023-10-26 Kvartalsrapport 2023-Q3
2023-08-24 Kvartalsrapport 2023-Q2
2023-05-03 Kvartalsrapport 2023-Q1
2023-03-29 Årsstämma 2023
2023-02-17 Bokslutskommuniké 2022
2022-12-09 Extra Bolagsstämma 2022
2022-10-26 Kvartalsrapport 2022-Q3
2022-08-15 Kvartalsrapport 2022-Q2
2022-04-28 Kvartalsrapport 2022-Q1
2022-04-19 Ordinarie utdelning SOFTX 0.00 NOK
2022-04-17 Årsstämma 2022
2022-02-16 Bokslutskommuniké 2021
2021-12-29 Extra Bolagsstämma 2021
2021-11-17 Kvartalsrapport 2021-Q3
2021-09-08 Kvartalsrapport 2021-Q2
2021-04-29 Kvartalsrapport 2021-Q1
2021-04-14 Ordinarie utdelning SOFTX 0.00 NOK
2021-04-13 Årsstämma 2021
2021-02-09 Bokslutskommuniké 2020
2020-12-14 Kvartalsrapport 2020-Q3
2020-09-30 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning SOFTX 0.00 NOK
2020-06-30 Årsstämma 2020
2020-06-30 Kvartalsrapport 2020-Q1
2019-12-20 Extra Bolagsstämma 2019
2019-06-27 Årsstämma 2019
2019-06-03 Ordinarie utdelning SOFTX 0.00 NOK
2018-07-02 Split SOFTX 1:50

Beskrivning

LandNorge
ListaMERK Equities
SektorHälsovård
IndustriMedicinteknik
SoftOx Solutions är ett norskt medicintekniskt bolag. Bolaget har utvecklat en egenpatenterad lösning baserad på ättiksyra för behandling av kroniska sår hos patienter. Lösningen används för att eliminera infektioner i samband med biofilmer, vilket består av olika kluster av bakterier. En del av läkemedelsutvecklingen sker i samarbete med övriga forskningsinstitut. SoftOx Solutions etablerades under 2012 och har sitt huvudkontor i Oslo.
2022-10-19 07:32:17
OSLO - October 19, 2022: Softox Solutions AS ("SoftOx" or the "Company"), a
medtech and clinical-stage pharmaceutical company with a separate disinfection
branch in Norway, today received the final approval on its application for the
SoftOx biocidal product family for hand- and surface disinfection from the
Swedish Chemicals Agency (KemI). This approval allows SoftOx to sell its
disinfection products in Sweden.

"This is a great day for SoftOx," said Geir Almås, CEO of SoftOx Solutions.
"When we decide to enter other European markets, this approval will strongly
increase the probability of our disinfection products being approved by the EU.
Following our business development strategy, we will now carefully evaluate the
opportunities to partner up with suitable companies that can bring our
disinfection technology to market," Almås continued.

SoftOx can use this approval as a basis for new applications - mutual
recognition in sequence - in any European market. As the Swedish authorities
have diligently evaluated and approved the application, the mutual recognition
process, described in the Biocidal Products Regulation (BPR), is considered a
less complex and less expensive process.

"This approval documents that our technology is valid and that the products are
effective and safe. I am proud of the team, which has successfully seen this
project through to where we are today," said Hans Jørgen Holum, SoftOx's Project
Manager of Biocides.

A safe and effective alternative to alcohol-based disinfectants
In addition, this approval may provide opportunities in markets outside Europe
that normally rely on either EU or US regulatory decisions.

"This approval comes in addition to several other documented advantages of our
solution. We have reference customers in Norwegian and Swedish hospitals and
clinical documentation of skin friendliness. The Norwegian Defence Research
Establishment (FFI) also published a positive data analysis, which showed that
the SoftOx disinfectant reduced the level of volatile organic compounds in the
air during an intervention period by 30-60% when compared with alcohol-based
disinfectants, improving employees' health, safety and environment. With this
approval in place, we are confident moving forward with our unique and effective
disinfectant technology for both civil and military applications," said Almås.

For further information, please contact:
Geir Almås, CEO of SoftOx Solutions AS
Mail: ir@soft-ox.com
Phone: Front Desk: (+47) 948-59-599

The information included in this announcement is defined as inside information
pursuant to MAR article 7, and is publicly disclosed in accordance with MAR
article 17. The announcement is made by the contact person.

About SoftOx Solutions AS
SoftOx Solutions AS (SoftOx, listed on Euronext Growth Oslo) is a Norwegian
medtech and clinical-stage pharmaceutical company based in Oslo, Norway, with
the goal of reducing the spread of infection and emergence of antimicrobial
resistance. For more information on SoftOx, visit www.soft-ox.com